Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...
Abdullah also attributed GSK’s willingness to go all-in on mo-rez on the leadership of Luke Miels, who stepped up as CEO of ...
With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...
Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results